Health
Synairgen’s SNG001 advances into phase 3 COVID-19 trial – PMLiVE
UK biotech had initially been testing drug for COPD and asthma
Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing.
SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation – INF-beta is a naturally occurring protein that controls the body’s antiviral response.
Initially, Synairgen had been evaluating the drug as a treatment for COPD and asthma, although its focus has now shifted to investigating…
-
Noosa News15 hours agoMitch Power Quick Shear event gets men talking about mental health
-
General17 hours agoThailand punches above its weight in film creativity and cross-border appeal. Here’s why
-
General10 hours agoAFL Round 18 live updates: Bulldogs vs Crows, Giants vs Cats, Tigers vs Bombers, Dockers vs Hawks — blog, scores and stats
-
Noosa News18 hours agoRaising your voice | Noosa Today